Placeholder Banner

BIO Statement on Proposed Maryland Drug Pricing Legislation

January 10, 2017

Washington, D.C. (January 10, 2017) – The Biotechnology Innovation Organization today released the following statement regarding proposed drug pricing legislation within the Maryland Senate:

“Any legislative effort to address the affordability of medicines must be patient centered, holistic, and promote patient access to treatments and cures. Biotechnology innovation is not only providing enormous benefits to patients and value to the healthcare system, but it is a proven job creator, employing over 34,000 Marylanders in good, high-paying jobs, with billions invested in the state annually. BIO will oppose legislative proposals that could harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through heavy-handed government intrusion.”

###

Discover More
New focus on justice through equity in diverse clinical trials, STEM education and expanding entrepreneurship to undeserved communities will drive nation’s largest life science advocacy organization The Biotechnology Innovation Organization (BIO)…
Today, the Biotechnology Innovation Organization (BIO) submitted its comments in response to the U.S. Department of Agriculture’s (UDSA) Solicitation of Input from Stakeholders on Agricultural Innovations, part of the Department’s Agriculture…
Washington, D.C. (July 29, 2020) – The Food and Agriculture Section of the Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Board leadership. Sylvia Wulf, CEO of AquaBounty Technologies, Inc., and Brian…